Weiss Ratings has once again assigned RxSight a “sell (E+)” rating. Another research analyst, Wall Street Zen, similarly adjusted its stance from “hold” to “sell,” indicating a continued sense of caution around RxSight’s stock.

Robbins Geller Rudman & Dowd LLP has filed a class action lawsuit against RxSight, Inc., claiming that top executives made false and misleading statements in violation of federal securities laws. Investors who suffered substantial losses are encouraged to join the lawsuit before the September 22, 2025 deadline.